New drug LAE102 passes first safety check in healthy women
NCT ID NCT06908707
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug called LAE102 in 32 healthy postmenopausal women to see if it is safe and how the body processes it. Participants received either a single dose of LAE102 or a placebo. The main goal was to check for side effects, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Trials
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.